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Abstract
Aim.  Objective  of  the  study  was  to  determine  the  most  common cutaneous  lesions  in  patients  with 
haematologic malignancies observed at dermatologic consultation and to identify the impact parameters 
related  to  the  haematologic  condition,  like  disease  type/duration,  remission,  chemotherapy  and 
transplantation, have on skin manifestations.
Methods.  A  total  of  101  consecutive  patients  with  onco-haematological  malignancies  referred  for 
dermatological   consultation  over  a  two-year  period  were  included  in  this  prospective  single-centre 
observational cohort study.
Results. The most common finding was infection (19.8%), followed by drug adverse reactions (16.8%) and 
malignant  neoplasia  (11.9%).  Elderly  patients  and  those  with  a  longer  disease  duration  had  a  higher 
frequency of cutaneous neoplasia. Squamous cell carcinoma was the most frequent cutaneous neoplasia; 
three cases of melanoma were diagnosed and had a high Breslow thickness. Cutaneous involvement due to 
the haematological malignancies was observed in 5 patients. Common chronic dermatoses (psoriasis and 
eczema)  were found in  10% of  patients.  Transplant  had no effect  on  the percentage of  infections  or 
tumours.
Conclusion. Patients with haematological malignancies have a higher incidence of adverse drug reactions 
with peculiar morphologic features and a lower incidence of common chronic dermatoses than patients 
referred for dermatological consultation by their general practitioner or other hospital services. Infectious 
dermatoses were less frequent than in solid organ transplanted patients. The complex variety of cutaneous 
lesions,  the differential  diagnostic pitfalls  and the prognostic relevance of early skin tumour diagnosis, 
evidence the importance of a correct dermatological approach.
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Onco-hematological patients have a severely impaired immune homeostasis, which may be attributed to 
the disease itself, chemotherapy, graft-versus-host-disease (GvHD) and its treatment. Consequently, they 
present frequent and potentially severe infectious complications, that are a primary cause of mortality, 
particularly after allogeneic haematopoietic stem cell transplantation (HSCT). Moreover, long term survival 
HSCT patients have an increased risk of developing cancers, especially virus-related.1 
The skin is one of the major target organs for both infectious complications and cancer development. A 
recent study on more than 2000 transplant recipients reported the occurrence of skin diseases in 45% of 
patients.2  The  cumulative  incidence  of  cutaneous  tumours  increases  along  with  the  time  from 
transplantation; a series of papers, predominantly on kidney transplant recipients, showed a cumulative 
incidence  up  to  25%  with  a  significant  increase  paralleling  the  post-transplant  period.3-7  Cutaneous 
involvement is also a constant feature of acute and chronic GvHD, one of the major complications after 
HSCT and is responsible for a decrease in the quality of life and an increase in morbidity and mortality.8, 9 
Approximately 40-60% of patients develop GvHD after an allogeneic transplantation and almost all of them 
have cutaneous lesions. 
The challenging differential diagnosis of cutaneous lesions in these patients emphasises the need for a 
correct  dermatological  approach.  A  prospective  observational  trial  reported  that  dermatological 
manifestations had a significant impact on haematology practice:  45% of inpatients received topical  or 
systemic  skin  treatment,  5%  had  a  treatment  delay;  11%  of  patients  required  extra  nursing  and  3% 
prolonged  their  hospitalization  due  to  dermatological  lesions.10  Moreover,  a  recent  prospective 
multicenter study demonstrated a lack of agreement in 56.3% of cases between diagnosis suggested by 
“non-specialists”  and  dermatologists,  showing  that  common  dermatological  diseases   are  often  not 
recognized or misdiagnosed by non-dermatologists.11 
In spite of this evidence, to the best of our knowledge, there is no specific literature aimed at the analysis 
of the spectrum of cutaneous diseases in patients with haematologic malignancies. On the other hand, 
similar studies have been conducted in solid organ transplant recipients.12-16 These data prompted us to 
perform a prospective observational cohort study on patients with haematologic malignancies referred to 
our department for a dermatologic consultation, with the aim of determining the spectrum of skin lesions. 
Our secondary objective was to assess whether the cutaneous manifestations were affected by various 
parameters  related  to  the  hematologic  condition,  e.g.,  type  of  disease,  disease  duration,  remission, 
chemotherapy and/or bone marrow transplantation.
Materials and methods 
Patients 
This prospective observational study analyses the clinical records of all the consecutive patients referred for 
a dermatologic consultation on an out-patient or in-patient basis from the Haematological Departments of 
our hospital. After having obtained written informed consent, 101 patients were included over a two year 
period (Table I). Leukemia was the most frequent haematological disease (N.=47: 13 acute myeloid,6 acute 
lymphoblastic, 6 chronic myeloid and 20 chronic lymphocytic), 31 patients had non-Hodgkin lymphoma 
NHL), 14 multiple myeloma and 9 Hodgkin lymphoma. Sixty-eight of the patients (67.3%) had received 
previous treatment but  were not  on chemotherapy at  the time of the visit;  whilst  chemotherapy was 
ongoing  in  the  remaining  33  patients  and  10  of  these  had  three  cell  lineage  bone  marrow  aplasia. 
Allogeneic HSCT had been performed in 29 patients (2 with multiple myeloma, 2 Hodgkin’s lymphoma, 7 
NHL  and 18 with  leukaemia),  26  of  whom had had  myelo-ablative  HSCT.  Their  conditioning  regimens 
included different combinations of chemotherapic drugs (cyclophosphamide, busulfan, thio-tepa,  elphalan, 
fludarabine) with or without antithymocyte globulin and/or total body irradiation. Non-myeloablative HSCT 
had  been  performedin  3/29  patients  with  reduced  intensity  conditioning  regimen.  GvHD  prophylaxis 
following  full  intensity  conditioning  regimens  included  a  combination  of  a  calcineurin  inhibitor 
(cyclosporine, tacrolimus) and short course methotrexate. 
Overall, 48 patients were in haematological remission after chemotherapy with or without HSCT at the time 
of the visit.  All  patients were visited by the same dermatologists (PQ, TN, PS).  Any history of previous 
dermatological  diseases  and/or  skin  cancers  was investigated.  Skin  biopsy  was required  for  diagnostic 
purposes  in  32  cases;  immuno-histochemistry  was  used  to  assess  cutaneous  involvement  due  to 
haematological malignancy.
Statistical analyses
Haematologic disease duration was defined as the time from the date of first diagnosis to the date of first 
dermatological visit. Non parametric tests were applied to evaluate the distribution of variables and the 
differences in  the distribution  of  variables  were determined by  the Fisher’s  exact  test  and the Mann- 
Whitney U test.
Results
Cutaneous diseases 
The distribution of dermatological disorders as diagnosed in the total cohort is shown in Figure 1. The most 
frequent disease was infections,  observed in 20 cases (19.8%),  followed by adverse drug reactions (17 
cases, 16.8%). Twenty-three patients had been referred for a suspicion of skin malignancy, where clinical 
and histological examination confirmed ma- lignant tumour in 12 (11.9%), the other 11/23 had a benign 
neoplasia. A diagnosis of GvHD was made in 9 patients: four had acute GvHD with confluent erythematous 
edematous lesions and occasional bullae formation (Figure 2A, B), five had chronic GvHD with a lichenoid or 
sclerodermiform pattern (Figure 2C). Another 5/101 patients (4.9%) presented with papulo-nodular and/or 
nodular lesions and, on the basis of the clinical and histopathological features, a diagnosis of cutaneous 
involvement due to leukaemia was made in 2 cases, due to NHL in 2 and in 1 it was due to multiple yeloma 
(Figure 2 D-F). Common chronic dermatoses were diagnosed in a total of 11 patients, eczema in 5 (4.9%) 
and psoriasis, which was present at the time of first haematological diagnosis, in 6 (5.9%). The psoriasis 
worsened in 2/6 patients in association with the development of acute lymphoblastic and acute myeloid 
leukemia respectively, followed by a marked improvement after complete haematological remission. Two 
of  the 5 patients  with eczema had localized allergic  contact  dermatitis  and 3/5 were suffering  from a 
longstanding chronic eczema which had not been modified by the haematologic malignancy. Another 5/101 
patients showed immune-mediated dermatoses, i.e., lichenoid dermatitis in 2, 1 had epidermolysis bullosa 
acquisita,  1  erythema  nodosum  and  1  cutaneous  sarcoidosis;  two  of  these  patients  were  on 
immunosuppressive drugs after HSCT. Less frequent dermatological diseases included: prurigo (4 cases) and 
pityriasis rosea (3); another patient, who was affected by acute myeloid leukemia, had disseminated insect 
bite-like reactions17.
Infectious diseases
Infections accounted for 19.8% of cases (20 patients).
The most frequent causative agents were viruses (10 cases: 2 herpes simplex and one was disseminated; 3 
herpes zoster  and one was disseminated;  2 molluscum contagiosum and 3  viral  warts)  (Figure 3A,  B), 
followed by bacteria (6 cases, folliculitis and impetigo). Fungal infections were observed in 4 patients and 
3/4 had tinea corporis, intertrigo and ptyriasis versicolor respectively; the latter had disseminated papulo-
nodular  lesions  with  a  central  necrotic  and  ulcerated  area  associated  to  sepsis  by  Fusarium  spp.,  a 
filamentous fungus which constitutes one of the emerging causes of opportunistic mycoses. 
No  association  was  found  between  the  infectious  complications  and  the  haematological  malignancy, 
chemotherapy  administration,  aplasia  or  haematological  remission.  Similarly,  there  was  no  significant 
difference in the percentage of cutaneous infections diagnosed in allogeneic HSCT patients compared to 
the others (24.1% vs. 18.1%).
Adverse drug reactions
Adverse drug reactions occurred in 16.8% of cases (17 patients). The commonly involved causative agents 
were antibiotics e.g. penicillins, levofloxacine and sulfamethoxazole, ibuprofen, allopurinol and mucolytic 
agents.  Three patients developed a  drug reaction to  lenalidomide, used for  the treatment  of  multiple 
myeloma.  The  most  frequent  clinical  picture  was  an  exanthematic  maculo-papular  eruption  and  the 
presence of chemotherapy-associated thrombocytopenia determined the development of papulo-purpuric 
vasculitis- like lesions in the lower limbs in 4 patients. Three patients developed flexural erythema involving 
the inguinal, axillary and elbow folds, due to allopurinol, vancomycin and aracytine, respectively. Other 
manifestations were related to specific drugs. One patient treated with rituximab developed an urticarial 
eruption around the cutaneous NHL lesions (Figure 3C). One patient showed gingival hypertrophy after 
cyclosporin. Two further patients developed flagellate dermatitis, asymptomatic linear pigmented lesions 
on  the  trunk  and  shoulders  after  bleomycin  administration  (Figure  3D);  one  of  these  patients  also 
presented a nail pigmentation with radial stream. 
Drug  adverse  reactions  were  significantly  more  frequent  in  multiple  myeloma  (35.7%)  than  in  other 
haematologic malignancies (13.8%; P=0.05), in patients with ongoing chemotherapy (42.4%) compared to 
those  with  previous  chemotherapy  (4.4%;  P<0.001),  in  patients  who  did  not  achieve  haematological 
remission (24.5%) when compared to those who did (8.3%; P=0.03) and in patients in aplasia (40%) vs those 
with a normal blood cell count (19.8%) (borderline significance:P=0.06).
Cutaneous malignancies
A cutaneous neoplasia was diagnosed in 12 patients (11.9%). The most frequent cutaneous neoplasia was 
squamous cell  carcinoma (6 cases),  with one case localized in the oral  mucosa. One of these patients 
developed a regional node involvement during follow-up. Multiple actinic keratosis, mainly localized in the 
photo-exposed areas, were observed in 3 of these patients. Malignant melanoma was diagnosed in another 
3, with a Breslow thickness of 2 mm, 3.5 mm and 8.8 mm respectively (Figure 3E, F);  one patient had 
regional  cervical  node  metastases  at  diagnosis.  Two  NHL  patients  in  remission  after  chemotherapy 
developed mycosis fungoides, an indolent primary cutaneous T-cell lymphoma, with disseminated patches. 
Another patient, with Hodgkin lymphoma, developed a diffuse cutaneous Kaposi sarcoma concomitant with 
a late relapse of her hematological disease. 
Cutaneous neoplasia were most frequently ob- served in elderly patients (median age: 70.5 years) (Mann-
Whitney test:  P=0.0044 when compared to  patients  without  neoplasia)  and in  patients  with  a  longer 
disease duration (median 6.5 years) (P=0.02) (Figure 4A, B). Patients who had been given hematopoietic 
stem cell transplantation showed no higher risk of cutaneous neoplasia than those who had not (6.9% vs. 
13.9%).
Selected case-reports
A  total  of  3/101  patients  had  rare  dermatologic  diseases  that  were  specifically  associated  to  their 
hematologic malignancies. A female patient with multiple myeloma showed long-standing firm, yellowish 
or  red–orange  plaques  and  nodules  with  teleangiectasies  and  violaceous  borders,  that  although 
disseminated, had an unusual sparing of the periorbital area. The histologic picture revealed a band-like 
pattern of necrobiotic granulomatous inflammation, atypical giant cells, cholesterol clefts and plasma cells, 
characteristic  of  necrobiotic  xanthogranuloma 18  (Figure  2G).  This  entity  is  a  rare  non-X histiocytosis 
commonly associated with monoclonal gammopathies and multiple myeloma; the skin lesions develop as a 
reactive granulomatous inflammatory process,  not associated with the presence of monoclonal plasma 
cells. A second patient, with chronic lymphocytic leukaemia on rituximab, presented with erythematous 
edematous plaques with a central blistering, localized on the lower limb; the histological picture showed a 
marked cutaneous eosinophilia, fibrinoid “flame figures” and palisading granuloma, diagnostic for Wells’ 
syndrome, classified into the spectrum of eosinophilic cutaneous disorders 19 (Figure 2H). A third patient 
was a 41-year old female who, 1 year after allogeneic HSCT for acute myeloblastic leukaemia, developed 
disseminated small keratotic papules with a raised, ridge-like border and a thin central furrow and minimal 
scaling. The histologic picture showed the typical  cornoid lamella characteristic of disseminated Mibelli 
porokeratosis, a rare disorder of keratinisation usually seen in the clinical setting of immunosuppression 20 
(Figure 2I).
Discussion
This  prospective  clinical  study  aimed  at  determining  the  spectrum  of  cutaneous  diseases  in  onco- 
haematologic  patients  referred  for  dermatological  consultation  and  to  ascertain  whether  different 
haematologic malignancies and/or factors related to the haematologic conditions have an impact on skin 
manifestations. Although similar studies have been carried out in solid organ transplant recipients,12-14 to 
the best of our knowledge, no data are available in onco-haematologic patients with or without HSCT. 
Our  study  showed that  infections,  adverse  drug  reactions and neoplasia  are  the  three most  common 
cutaneous diseases found in onco-haematological  patients sent  for dermatological  consultation, which, 
when summed up, account for almost 50% of our cases. On the other hand only 9% of our patients were 
referred for  cutaneous  GVHD,  a  frequent  manifestation in transplanted patients.  This  unexpected low 
percentage implies that GVHD diagnosis is managed in the majority of cases by the haematologist, leaving 
dermatologic consultation only for the more challenging cases. Significant differences in the spectrum of 
dermatological  diseases  can  be  observed  between  onco-haematological  patients  and  outpatient 
dermatological consultations from the general practitioner or other hospital medical services, the former 
being characterised by a higher incidence of adverse drug derreactions with peculiar morphologic features 
and a lower relevance of common chronic dermatoses (eczema and psoriasis). Conversely, the percentage 
of infectious dermatoses was unexpectedly similar between the two groups and significantly lower than the 
figures reported for solid organ transplant patients. 
The  distribution  of  infections,  adverse  drug  reactions  and  neoplasia  was  analysed  vis-à-vis  with  the 
haematological conditions. HSCT patients did not show any significant increase in infections or neoplasia, 
suggesting that the immune homeostasis is already deeply impaired by multi-drug chemotherapies. Only 3 
patients in our series underwent non myeloablative HSCT: therefore, the potential reduction in neoplasia or 
infectious complications could not be evaluated.  Multiple myeloma patients had a higher frequency of 
adverse drug reactions. The drugs most frequently involved as causative agents were the same as in the 
general population i.e. antibiotics, ibuprofen, allopurinol and mucolytic agents; the reaction was aroused by 
lenalidomide  in  3  patients,  which  had been  used for  the  treatment  of  myeloma21,22.  The  significant 
increase of adverse drug reactions in patients with ongoing chemotherapy is related to the higher number 
of drugs taken by these patients. This may well also ccounts for the development of adverse drug reactions 
in patients with aplasia, even if it is hardly understandable how such immune-suppressed patients with 
markedly reduced white blood cell counts could develop an allergic or immune-mediated reaction. Adverse 
drug reactions in onco-haematological patients may have peculiar morphologic features, including flexural 
erythema,  urticarial  eruptions  around  the  cutaneous  NHL  lesions  (rituximab),  flagellate  dermatitis 
(bleomycin) and nail pigmentation. Flexural erythema, where the term systemic drug-related intertriginous 
and flexural exanthema has recently been proposed, has also been reported in literature in healthy people. 
Indeed, it is considered to derive from an interplay between a delayed-type immune reaction and local 
factors such as  friction, local  skin temperature and eccrine gland distribution, which might explain the 
characteristic skin location of this eruption.23 Apart from infections, adverse drug reactions and neoplasia, 
the  remaining  50% of  the  patients  included  in  this  study  had  a  variety  of  cutaneous  manifestations, 
including skin involvement  by  the haematologic disorder,  e.g.,  such as leukemia cutis,  GvHD,  psoriasis, 
eczema, lichenoid dermatitis, epidermolysis bullosa acquisita, erythema nodosum, cutaneous sarcoidosis, 
prurigo and pruritus, pityriasis rosea, necrobiotic xanthogranuloma, Wells’ syndrome, Mibelli porokeratosis 
and insect  bite-like  reactions.  As  to psoriasis,  it  is  interesting to observe that the development  of  the 
haematologic  malignancy  gave  raise  to a  significant  worsening  of  the  cutaneous  manifestation,  which 
improved after chemotherapy and haematologic remission. This finding emphasizes the strong influence 
haematologic diseases have on skin patho-physiology. In fact, the release of pro-inflammatory cytokines 
and soluble mediators induced by the haematologic neoplasia might well constitute the molecular trigger 
for the worsening of psoriasis which may then go on to improve with haematologic remission. 
The spectrum of dermatological diseases in oncohaematological patients differs from what is observed in 
outpatient dermatological consultations referred from the general practitioner or other hospital medical 
services. In a series from the south east of Scotland, 24 2% of visits were for adverse drug reactions, whilst 
23.4%  were  for  psoriasis  and  eczema.  Eczema  alone  accounted  for  22.5%  of  general  practitioner 
consultations with a dermatological basis in another  report.25 In a recent prospective cohort study carried 
out by the Dermatology Departement of a Spanish hospital, all inpatient consultations performed over a 1 
year period were analysed. Inflammatory dermatosis was the most common diagnosis (35.8%, 160/429 
patients), followed by infectious dermatosis (25.7%), while adverse drug reactions accounted for 8.7% of all 
visits.26 Another series from a Portoguese hospital, showed skin infections (33.2%), eczemas (9.5%) and 
drug eruptions (7.3%) to be the most common diagnoses27. Only a few patients in our onco-haematologic 
patients had a diagnois of psoriasis or eczema (5.9%and 4.9%, respectively); this could be due to the fact 
that treatment for haematologic malignancies and the prevention of GvHD, e.g., steroids, cyclosporine, can 
induce remission of eczema and psoriasis in a significant percentage of cases. In patients coming from other 
medical services for dermatological consultation, drug eruptions were reported to vary between 4.2% 28 
and 14%,26, 29 whilst our series had 16.8%. Indeed, in a recent retrospective study on more than 4000 
inpatient  dermatologic  visits  performed  for  different  referral  services,  the  most  common diagnosis  in 
patients from the Medical  Haematology department was drug eruption, which accounted for 12.2% of 
visits.30  However,  noteworthy  is  the  fact  that  the  percentage  of  cutaneous  neoplasia  and  infectious 
derreactions matoses in onco-haematologic patients was similar to that reported in literature for both 
inpatient and outpatient dermatologic consultations. Conversely,  higher values can be expected on the 
basis of the immunesuppression which characterizes these patients. In fact, the percentage of visits for 
cutaneous malignant neoplasia in general outpatient referrals was similar (11.6%) 24 when compared to 
our series (11.9%). This finding is not in contrast with the well-proven higher risk of tumours in transplant 
recipients, where most of these patients undergo regular dermatological consultations, which, on the other 
hand, are carried out only in a minority of the general population. Thus, in spite of a similar percentage of 
cutaneous neoplasia observed in the dermatological visits, the true incidence of skin tumours in immune-
suppressed  and  transplant  patients  is  exceedingly  high.  As  to  infectious  dermatoses,  Fisher  et  al.31 
reported 24.4% of outpatient cases,  Itin  et al.  21.7%,32 in line with our findings.  In other studies,  the 
percentage of infectious diseases was either lower (11% in a French report),33 or higher (29.8% in an Indian 
Hospital). 34 These differences may, in part, be attributed not only to the services analysed (surgery wards 
have a high incidence of infectious complications), but also to the geographic area and the pateints’ social 
conditions.  In  spite of a similar  percentage,  infectious dermatoses  in  onco-haematological  patients  are 
more severe and disseminated than are immune-competent outpatient cases. 
Moreover, a small percentage of patients in our series (<10%) underwent dermatological evaluation for the 
onset of cutaneous lesions related to chemotherapy or the underlying onco-haematological disease, such 
as petechiae, ecchymosis and purpura. These conditions, also known as non specific “leukemids”, are a 
frequent finding in these patients and need to be differentiated with care from the “specific” lesions due to 
skin involvement by the underlying hematologic disease.35 
The distribution of cutaneous diseases in onco-hematological patients was also compared to what has been 
reported for  solid  organ transplant  recipients.  A  series  of  studies  have  reported that  renal  transplant 
recipients run a high risk of developing cutaneous infections. The largest series reported includes 801 organ 
transplant  recipients  with  dermatological  manifestations,  where  46%  of  cases  showed  cutaneous 
infections.6 In an Italian series of 109 kidney transplant patients,36 40% of patients with dermatological 
manifestations had cutaneous infections. Other papers reported higher percentages,  between 55% and 
66%.37-39 
In a recent study performed by our group on 282 kidney transplant patients, 99 patients (35.1%) developed 
cutaneous tumours after transplantation, whilst infectious diseases were observed in 16.7% of cases.40 
Cutaneous  infections  appear  even  more  frequent  in  liver  41  and  heart  42  transplant  patients,  whith 
percentages as high as 70% of cases. As in our series, viruses and fungi were the most common etiological 
agents  in  all  these  series.43  The  heavier  immunosuppressive  load  of  longer  duration  in  solid  organ 
transplant patients probably accounts for the higher frequency of cutaneous infections compared to onco-
haematological patients.44 On the other hand, the percentage of cases diagnosed with skin cancer is quite 
similar  in  our  series  to what  has  been observed in  solid  organ transplant  recipients.  Pre-malignant  or 
malignant skin lesions have been documented in literature in a varying percentage of patients, i.e., up to 
35% 2-7, 36, 38-45 and almost all the cases were non melanoma skin cancer. However, 3 of our patients 
had cutaneous melanoma and all had with a thick primary (2 mm or more) metasteses and 1/3 had nodal 
metastases.  One of  these cases  was a nodular  melanoma of recent  onset,  whilst  the lesion had been 
present  for  more than 1  year  in  the  other  two  cases.  Melanoma prognosis  depends  on the  Breslow 
thickness; moreover, the prognosis of post-transplant melanoma >2 mm is even poorer than that of the 
general  population.46  These  data  further  emphasise  the  need  for  accurate  periodic  dermatologic 
examinations,  particularly  in  elderly  people  with  a  longer  disease  duration,  so  as  to  favour  an  early 
diagnosis and, consequently, improve survival. 
In  conclusion, the complex variety of cutaneous lesions encountered in these patients,  the challenging 
differential diagnosis and the need for an early identification of cutaneous neoplasia, clearly underline the 
usefulness of a correct dermatological approach.
Riassunto
Spettro  delle  patologie  cutanee  nei  pazienti  affetti  da  neoplasie  ematologiche,  con  o  senza  trapianto  
allogenico di midollo: studio osservazionale in 101 pazienti 
Obiettivo. Determinare la varietà di lesioni cutanee osservabili nei pazienti onco-ematologici che vengono 
inviati ad un controllo dermatologico e determinare l’influenza Dermadella malattia di base (in termini di 
tipo e durata della malattia, eventuale remissione, chemioterapia, trapianto) sulle manifestazioni cutanee.
Metodi. In questo studio prospettico osservazionale sono stati inclusi tutti i pazienti con patologie onco-
ematologiche inviati per una visita dermatologica in un periodo di tempo di 2 anni.
Risultati. Nei 101 pazienti analizzati, le patologie più rappresentate sono state infezioni (19,8%), reazioni 
avverse a farmaci (16,8%) e neoplasie maligne (11,9%). I  tumori cutanei sono risultati più frequenti nei 
pazienti  anziani  ed  in  quelli  con  malattia  di  lunga  durata.  Il  più  diagnosticato  è  stato  l’epitelioma 
spinocellulare; tre sono stati i casi di melanoma. Cinque pazienti presentavano un interessamento cutaneo 
della malattia ematologica di base. Psoriasi ed eczema sono state osservate in una minoranza dei pazienti. 
Nei soggetti trapiantati non si è riscontrata una maggiore percentuale di infezioni né di tumori cutanei. 
Conclusioni.  Rispetto  ai  pazienti  che  accedono  ad  una  visita  dermatologica  generica,  i  pazienti  onco-
ematologici sono caratterizzati da una maggiore incidenza di reazioni avverse a farmaci, spesso con aspetti 
clinici peculiari e da una minor frequenza delle dermatosi croniche più comuni. Le dermatosi infettive sono 
meno frequenti rispetto ai pazienti con trapianto di organo solido. La complessa varietà di lesioni cutanee 
che  si  possono  riscontrare  in  questi  pazienti,  la  difficoltà  nella  diagnosi  differenziale  e  la  rilevanza 
prognostica della diagnosi precoce dei tumori cutanei sottolineano la rilevanza di un corretto approccio 
dermatologico.
Parole chiave: Dermatosi - Farmaci, tossicità – Neoplasie ematologiche - Trapianto di midollo osseo.
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Figure  1.—Distribution  of  dermatological  diseases  and  manifestations.  *  Other:  specific  dermatoses 
frequently associated with haematologic malignancies.
Figure 2.—Representative clinical pictures in patients with onco-haematological malignancies. A) bullous 
acute  GvHD;  B)  diffuse  acute  GvHD;  C)  sclerodermiform  deeply  indurated  chronic  GvHD;  D)  peculiar 
manifestations  of  chronic  lymphocytic  leukaemia  localisations  with  vescico-bullous  annular  lesions;  E) 
erythematous edematous annular cutaneous localisations of acute lymphocytic leukaemia;  F)  a nodular 
infiltrated  lesion  in  a  patients  with  NK  lymphoma  Epstein-Barr  virus  related;  G)  necrobiotic 
xanthogranuloma; H) Wells’ syndrome; I) Mibelli porokeratosis.
Figure 3.—Infectious dermatoses: A) left shoulder herpes zoster with disseminated lesions; B) giant viral 
wart localized in the palm of  the left  hand.  Adverse drug reactions:  C)  urticarial  reaction to rituximab 
localized at the site of cutaneous NHL lesions; D) bleomycinrelated flagellate dermatitis. Skin tumours: E) 
acromic nodular phase of a superficial spreading melanoma of the scalp, Breslow thickness 8.8 mm; F) 
ulcerated acral lentigginous melanoma of the foot, Breslow thickness 3.5 mm.
Figure 4.—Skin neoplasia in patients with onco-haematological malignancies. The development of a skin 
malignant tumour is significantly more frequent in elderly patients (A) and in patients with a longer disease 
duration. Each dot represents a patient; horizontal bars represent median values. * P<0.05; ** P<0.005.
